Intelligent Bio Solutions Inc. filed its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission covering the fiscal year ended June 30, 2026, disclosing company financials, risk factors, and governance information as a smaller reporting company listed on NASDAQ:INBS.

Key Highlights

  • Fiscal year covered: The annual report covers the period ended June 30, 2026.
  • Shares outstanding: As of August 18, 2026, the company reported 3,027,470 shares of common stock issued and outstanding.
  • Non-affiliate market cap: The aggregate market value of common stock held by non-affiliates was $11,712,017, based on the closing price on December 31, 2025.
  • Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
  • Going concern noted: The filing lists "our ability to continue as a going concern" among its forward-looking statement topics, according to the cautionary note in the report.
  • Principal offices: Intelligent Bio Solutions Inc. is headquartered at 135 West 41st Street, 5th Floor, New York, NY 10036.

Intelligent Bio Solutions Annual Filing: Company Profile and Key Disclosures

Intelligent Bio Solutions Inc. (NASDAQ:INBS), a Delaware-incorporated company with an IRS Employer Identification Number of 82-1512711, filed its Form 10-K annual report for the fiscal year ended June 30, 2026. The filing was submitted under Commission File Number 001-39825. The company's common stock carries a par value of $0.01 per share and is listed on The Nasdaq Stock Market LLC under the trading symbol INBS. No securities are registered under Section 12(g) of the Act, according to the filing.

The company confirmed it has filed all required Exchange Act reports during the preceding 12 months and has submitted all required Interactive Data Files electronically. The registrant indicated it is not a shell company. The filing notes that the Section 404(b) attestation on internal control over financial reporting by the registered public accounting firm was not required, consistent with its smaller reporting company classification.

The annual report's cautionary language identifies several areas of uncertainty the company considers forward-looking, including, as stated in the filing: "our ability to continue as a going concern," "our ability to successfully develop and commercialize our drug and diagnostic tests," and "our ability to secure regulatory approvals or clearance." These statements are the company's own, subject to the cautionary language contained within the filing. The report's table of contents reflects coverage across four parts, including business description, risk factors, management's discussion and analysis, financial statements, and executive compensation disclosures.

What Was Disclosed

Intelligent Bio Solutions Inc. filed its Form 10-K for the fiscal year ended June 30, 2026, reporting 3,027,470 shares outstanding as of August 18, 2026, a non-affiliate market value of $11,712,017 as of December 31, 2025, and its classification as a smaller reporting company.